NEW LIMITATION CHANGE

TO
Approved for public release, distribution unlimited

FROM
Distribution authorized to U.S. Gov’t. agencies only; Proprietary Info.; Sep 2001. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Ft. Detrick, MD 21702-5012.

AUTHORITY
USAMRMC ltr, dtd 28 July 2003
Award Number: DAMD17-00-1-0663

TITLE: Decorin, a Novel Anti-Tumor Agent that Blocks Breast Cancer Growth

PRINCIPAL INVESTIGATOR: Renato V. Iozzo, M.D.

CONTRACTING ORGANIZATION: Thomas Jefferson University
Philadelphia, Pennsylvania

REPORT DATE: September 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Sep 01). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-00-1-0663
Organization: Thomas Jefferson University

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure, or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release, or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure, or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

[Signature]
2/5/02
<table>
<thead>
<tr>
<th>1. AGENCY USE ONLY (Leave blank)</th>
<th>2. REPORT DATE</th>
<th>3. REPORT TYPE AND DATES COVERED</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>September 2001</td>
<td>Annual (01 Sep 00 - 31 Aug 01)</td>
</tr>
</tbody>
</table>

### 4. TITLE AND SUBTITLE
Decorin, a Novel Anti-Tumor Agent that Blocks Breast Cancer Growth

### 6. AUTHOR(S)
Renato V. Iozzo, M.D.

### 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Thomas Jefferson University
Philadelphia, Pennsylvania

**E-mail:** Iozzo@lac.jci.tju.edu

### 13. ABSTRACT (Maximum 200 Words)
Decorin is a prototype member of a family of the so-called small leucine-rich proteoglycans. Recent evidence has shown that decorin down-regulates the growth of a variety of tumor cells including breast carcinoma cells. Specifically, we have previously shown that decorin blocks the ErbB2 activity and, therefore, we believe that this is the mechanism that is utilized by decorin-induced growth inhibition. In the past funded year, we have made an attempt to generate adeno-associated viral vector (AAV2) containing decorin. After several negative attempts, we were successful in generating an AAV1-decorin vector. In preliminary studies, we have shown that this vector is capable of transducing various tumor cell lines and generating decorin. We have requested and obtained a one-year, no cost extension to pursue the AAV1 transduction experiments both in vitro and in vivo, in an animal model of orthotopic breast cancer.
Table of Contents

Cover

SF 298

Table of Contents

Introduction

Body

Key Research Accomplishments

Reportable Outcomes

Conclusions

References

Appendices

N/A
INTRODUCTION

Decorin, a prototype member of the small leucine-rich proteoglycan gene family, is emerging as a powerful modulator of cell growth because of its ability to affect matrix assembly, growth factor binding and receptor tyrosine kinase activity. The central hypothesis of our research is that the decorin gene, delivered by adenoviral or adeno-associated virus (AAV2) vectors directly to the tumor site, will reduce the growth of solid tumors such as breast, colon and squamous carcinomas (1-5).

BODY OF WORK

In the past year we have worked actively on generating an AAV2 vector containing the human decorin gene. We have obtained the AAV2-decorin vector and tested on two breast carcinoma cell lines, namely MDA-468 and MDA-453. Unfortunately, after several attempts of transduction with the AAV2-decorin vector, we could not find any expression of decorin either by RT-PCR or Western immunoblotting. We then made another construct in which the vector was changed to AAV1 and was modified to include a 400 bp deletion. Just recently, we found the first evidence for the presence of decorin. Thus we plan to test AAV1-decorin vector in the next year.

We have requested and obtained a one year, no-cost extension from the Department of the Army, in order to continue this project.

KEY RESEARCH ACCOMPLISHMENTS

We were able to generate a vector that could be used in future studies to target breast cancer cells in vivo. This vector is based on the latest generation of AAV1, adeno-associated virus 1, which can conceivably induce the expression of decorin in the tumor cells and thus retard the growth of breast carcinoma. This vector could potentially be delivered systemically.

REPORTABLE OUTCOMES

At this moment there are no reportable outcomes.

CONCLUSIONS

We have demonstrated that it is possible to generate an AAV1 vector containing decorin and that this vector can efficiently transduce tumor cell lines. These preliminary studies are encouraging and suggest that we will be able to pursue the study of breast cancer cells in vitro and the treatment of animal models of breast cancer as originally planned.

REFERENCES


MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

[Signature]

PHYLIS M. RINEHART
Deputy Chief of Staff for Information Management